Crystalys Therapeutics Launches Phase 2 Study for Gout Treatment Dotinurad

Crystalys Therapeutics Inc., a biopharmaceutical company focused on delivering innovative treatments for gout, has officially commenced dosing its first patients in the Phase 2 AMETHYST clinical trial. This study aims to assess the efficacy of Dotinurad, a novel oral medication designed for patients affected by gout, specifically those who have had adverse reactions to existing standard treatments, known as xanthine oxidase inhibitors (XOIs), or have experienced failures with uricase therapy.

About Dotinurad

Dotinurad stands out as a next-generation URAT1 inhibitor, which is taken once daily and shows promise as a leading contender in safety and effectiveness for gout management. James Mackay, President and CEO of Crystalys Therapeutics, expressed that reaching this milestone signifies a crucial step for both the company and the community suffering from gout. He emphasized the importance of expanding treatment options for patients with limited avenues available to them.

Dr. Nihar Bhakta, Chief Medical Officer at Crystalys, noted that a significant portion of gout patients are unable to utilize existing therapies to achieve their target uric acid levels, leading to recurrent gout attacks. He believes that Dotinurad addresses a substantial gap in treatment solutions for these individuals.

Overview of the AMETHYST Study

The AMETHYST study, registered under NCT07535034, is a randomized, double-blind, placebo-controlled trial set in the United States. It will encompass approximately 90 participants who have either shown a lack of tolerance towards XOIs or have contraindications against them.

The trial consists of two parts:
1. A 24-week placebo-controlled phase, where participants will receive either Dotinurad or a placebo (known as Treatment Period 1).
2. A subsequent 12-week active treatment phase, where all participants will receive Dotinurad (referred to as Treatment Period 2).

This clinical trial is fundamental in advancing Crystalys’s comprehensive development program, which also includes the ongoing Phase 3 RUBY and TOPAZ trials.

Understanding Gout

Gout is recognized as one of the most prevalent forms of inflammatory arthritis, often leading to debilitating pain accompanied by sudden and severe episodes of swelling, redness, and tenderness in affected joints. The condition is caused by elevated uric acid levels, termed hyperuricemia, which triggers the formation of uric acid crystals, resulting in inflammation and pain. In chronic cases, patients may develop tophaceous gout, emphasizing the need for effective treatment.

Despite the availability of therapies aimed at lowering uric acid levels, such as XOIs and uricase, many patients find themselves without viable second-line treatment options in the U.S. and Europe, underscoring the critical unmet medical need Crystalys aims to address through Dotinurad.

About Crystalys Therapeutics

Founded with the mission to revolutionize gout treatment, Crystalys Therapeutics is located in San Diego, California. Co-founded by Catalys Pacific and Novo Holdings, the company is comprised of a dedicated team with substantial expertise in gout drug development. Dotinurad, recognized for its safety and efficacy, has already received regulatory clearance in several Asian nations, with efforts underway to secure approval for commercial launch in other markets, including the U.S. and E.U.

In conclusion, the commencement of the AMETHYST study reflects Crystalys Therapeutics’ unwavering commitment to improving life for gout patients globally. Their ambitious approach not only seeks to discover effective solutions but aims to fill significant voids in current treatment paradigms for this challenging and often unpleasant condition.

For more information regarding Crystalys Therapeutics and their innovative solutions, visit their official website at www.crystalystx.com and connect with them on social media platforms like X and LinkedIn.